NEW YORK (GenomeWeb News) – Pace Claims Service will provide educational and marketing services on behalf of Rosetta Genomics for its miRview meso diagnostic test for mesothelioma under an exclusive marketing deal announced today.
Pace will provide its services to defendants and insurers involved in mesothelioma legal cases, and market miRview meso as a tool for cancer diagnosis, "thereby potentially saving defendants who might otherwise pay millions to claimants who were misdiagnosed with mesothelioma," Rosetta said in a statement.
Financial and other terms of the deal were not disclosed.
Citing statistics from the World Health Organization, Rosetta said that between the years 2000 and 2004 about 2,500 Americans died from mesothelioma in the US. During the same period there were 27,000 mesothelioma deaths outside the US.
The potential market for miRview meso is more than 2,000 new claims and more than 8,000 claims currently pending in the US, said Rosetta.
"This marketing agreement expands our commercial strategy for the miRview product line and augments our recently launched sales efforts in the US aimed at marketing our diagnostic products to pathologists and oncologists at leading cancer institutions and clinics," Rosetta President and CEO Kenneth Berlin said.
Pace is a wholly owned subsidiary of Navigant Consulting and provides asbestos claims administration. Exposure to asbestos is a leading risk factor in developing mesothelioma.